The experts discuss a case presentation of a 63-year-old woman with relapsed HER2+ metastatic breast cancer and discuss rate of relapse in this patient population.
Relapsed/Refractory HER2+ Metastatic Breast Cancer
Experts discuss the treatment considerations for HER2+ metastatic breast cancer and provide an overview of the DESTINY-Breast01 trial.
The experts have a detailed conversation on the HER2CLIMB trial, including third-line treatment options and the importance of having a detailed and balanced conversation with patients.
The panelists discuss clinical experience with the HER2CLIMB regimen, including main adverse effects.
The experts present and discuss a case of a patient with relapsed HER2+ metastatic breast cancer with stable brain metastases.
The experts discuss data from clinical trials of metastatic breast cancer with brain involvement.
Key opinion leaders consider later-lines of therapy in metastatic breast cancer with lung and brain involvement.
A panel of experts review the tucatinib regimen including adverse effects to keep an eye on.
Presentation and considerations for relapsed HER2+ metastatic breast cancer with progressing brain metastases.
Experts have a detailed conversation on the NALA trial of neratinib and capecitabine for HER2+ metastatic breast cancer.
The experts describe the SOPHIA study of margetuximab in HER2+ advanced breast cancer.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
Safusidenib Shows Robust, Ongoing Responses in Grade 2 IDH1-Mutant Glioma
4
Sac-TMT Demonstrates Antitumor Activity, Safety in Urothelial Carcinoma
5
